A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY

Single agent immune checkpoint therapy has shown substantial and durable clinical activity in many tumor types; however, only a fraction of the patients could benefit from this approach. To improve beyond the anti-PD-1/PD-L1 treatment options, bispecific antibodies (BsAb) that combines PD-L1 blockad...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Baocun, Wu, Xuan, Gong, Shiyong, Lv, Zhou, Zhang, Nianying, Zhang, Yu, Naren, Gaowa, Wu, Danqing, Wu, Jianfu, Liu, Fan, Zhang, Rui, Wu, Chengbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370443/
http://dx.doi.org/10.1093/abt/tbad014.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370443/
http://dx.doi.org/10.1093/abt/tbad014.008

Ejemplares similares